Cost-Benefit Analysis of a Chlamydia trachomatis Vaccine Program in Adolescent Girls in the United States.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Hammerschlag, Margaret R
Smith-Norowitz, Tamar A
Journal titleJournal of the Pediatric Infectious Diseases Society
Publication Begin page296
Publication End page302
MetadataShow full item record
AbstractWith >1.4 million cases in the United States reported to the Centers for Disease Control and Prevention in 2012, Chlamydia trachomatis infection is a major public health concern. We examined the impact of a C trachomatis vaccination program using a decision-analysis model to estimate the effects of vaccination on C trachomatis-associated costs and morbidity.
We developed a Markov model considering a cohort of 2158117 US females aged 9 to 26 years. Morbidity, death, and healthcare-associated costs associated with chlamydial infection of mothers and fetuses/neonates were calculated over a 17-year time frame. We developed 2 major comparison arms, namely, a C trachomatis vaccination program and no C trachomatis vaccination program. Base-case efficacy and coverage were set to those of human papillomavirus in the United States with all variables, including efficacy and coverage, ranged in sensitivity analyses.
On the basis of a base-case analysis, a vaccination program would cost an estimated $710 million for a cohort of 2158117 women over a 17-year period, an increase of $41 million over having no vaccination program. A vaccination program would prevent 34000 cases of C trachomatis infection and 5976 cases of pelvic inflammatory disease.
A C trachomatis vaccination program results in increased cost to the healthcare system but averts significant morbidity and death.
CitationDitkowsky J, Rahman A, Hammerschlag MR, Kohlhoff S, Smith-Norowitz TA. Cost-Benefit Analysis of a Chlamydia trachomatis Vaccine Program in Adolescent Girls in the United States. J Pediatric Infect Dis Soc. 2018 Dec 3;7(4):296-302. doi: 10.1093/jpids/pix072. PMID: 28992068.
The following license files are associated with this item:
- Creative Commons
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivatives 4.0 International
- Cost-benefit analysis of Chlamydia trachomatis screening in pregnant women in a high burden setting in the United States.
- Authors: Ditkowsky J, Shah KH, Hammerschlag MR, Kohlhoff S, Smith-Norowitz TA
- Issue date: 2017 Feb 18
- Screening for Chlamydia trachomatis in asymptomatic women attending family planning clinics. A cost-effectiveness analysis of three strategies.
- Authors: Howell MR, Quinn TC, Gaydos CA
- Issue date: 1998 Feb 15
- Cost-effectiveness of Chlamydia vaccination programs for young women.
- Authors: Owusu-Edusei K Jr, Chesson HW, Gift TL, Brunham RC, Bolan G
- Issue date: 2015 Jun
- Control of Chlamydia trachomatis infections in female army recruits: cost-effective screening and treatment in training cohorts to prevent pelvic inflammatory disease.
- Authors: Howell MR, Gaydos JC, McKee KT Jr, Quinn TC, Gaydos CA
- Issue date: 1999 Oct
- Cost-effectiveness of screening programs for Chlamydia trachomatis: a population-based dynamic approach.
- Authors: Welte R, Kretzschmar M, Leidl R, van den Hoek A, Jager JC, Postma MJ
- Issue date: 2000 Oct